nodes	percent_of_prediction	percent_of_DWPC	metapath
Naratriptan—HTR1B—artery—atherosclerosis	0.00291	0.173	CbGeAlD
Naratriptan—HTR1D—artery—atherosclerosis	0.00282	0.167	CbGeAlD
Naratriptan—Photosensitivity reaction—Lovastatin—atherosclerosis	0.00276	0.00391	CcSEcCtD
Naratriptan—Dry skin—Niacin—atherosclerosis	0.00275	0.00391	CcSEcCtD
Naratriptan—Liver function test abnormal—Pravastatin—atherosclerosis	0.00273	0.00387	CcSEcCtD
Naratriptan—Bronchitis—Simvastatin—atherosclerosis	0.00272	0.00386	CcSEcCtD
Naratriptan—Dry skin—Pravastatin—atherosclerosis	0.00271	0.00385	CcSEcCtD
Naratriptan—Abdominal discomfort—Simvastatin—atherosclerosis	0.00271	0.00385	CcSEcCtD
Naratriptan—Photosensitivity reaction—Ezetimibe—atherosclerosis	0.0027	0.00384	CcSEcCtD
Naratriptan—Cramp muscle—Pravastatin—atherosclerosis	0.00266	0.00378	CcSEcCtD
Naratriptan—Neuropathy peripheral—Lovastatin—atherosclerosis	0.00264	0.00375	CcSEcCtD
Naratriptan—Neuropathy peripheral—Ezetimibe—atherosclerosis	0.00259	0.00368	CcSEcCtD
Naratriptan—Photosensitivity reaction—Simvastatin—atherosclerosis	0.00258	0.00366	CcSEcCtD
Naratriptan—Arrhythmia—Rosuvastatin—atherosclerosis	0.00255	0.00362	CcSEcCtD
Naratriptan—Angina pectoris—Niacin—atherosclerosis	0.00253	0.00359	CcSEcCtD
Naratriptan—Sinusitis—Lovastatin—atherosclerosis	0.00253	0.00359	CcSEcCtD
Naratriptan—Depression—Simvastatin—atherosclerosis	0.00251	0.00357	CcSEcCtD
Naratriptan—Bronchitis—Niacin—atherosclerosis	0.00249	0.00354	CcSEcCtD
Naratriptan—Angina pectoris—Pravastatin—atherosclerosis	0.00249	0.00353	CcSEcCtD
Naratriptan—Sinusitis—Ezetimibe—atherosclerosis	0.00248	0.00352	CcSEcCtD
Naratriptan—Neuropathy peripheral—Simvastatin—atherosclerosis	0.00247	0.00351	CcSEcCtD
Naratriptan—Sinusitis—Simvastatin—atherosclerosis	0.00236	0.00336	CcSEcCtD
Naratriptan—Photosensitivity reaction—Pravastatin—atherosclerosis	0.00233	0.00331	CcSEcCtD
Naratriptan—Depression—Pravastatin—atherosclerosis	0.00227	0.00322	CcSEcCtD
Naratriptan—HTR1B—blood vessel—atherosclerosis	0.00227	0.135	CbGeAlD
Naratriptan—Acute coronary syndrome—Pravastatin—atherosclerosis	0.00224	0.00319	CcSEcCtD
Naratriptan—Neuropathy peripheral—Pravastatin—atherosclerosis	0.00223	0.00317	CcSEcCtD
Naratriptan—Myocardial infarction—Pravastatin—atherosclerosis	0.00223	0.00317	CcSEcCtD
Naratriptan—Sweating—Niacin—atherosclerosis	0.00222	0.00315	CcSEcCtD
Naratriptan—HTR1D—blood vessel—atherosclerosis	0.0022	0.13	CbGeAlD
Naratriptan—Chills—Lovastatin—atherosclerosis	0.00217	0.00308	CcSEcCtD
Naratriptan—Cough—Rosuvastatin—atherosclerosis	0.00217	0.00308	CcSEcCtD
Naratriptan—Angiopathy—Ezetimibe—atherosclerosis	0.00215	0.00305	CcSEcCtD
Naratriptan—Immune system disorder—Ezetimibe—atherosclerosis	0.00214	0.00304	CcSEcCtD
Naratriptan—Sinusitis—Pravastatin—atherosclerosis	0.00214	0.00303	CcSEcCtD
Naratriptan—Alopecia—Lovastatin—atherosclerosis	0.00214	0.00303	CcSEcCtD
Naratriptan—Arthralgia—Rosuvastatin—atherosclerosis	0.00211	0.003	CcSEcCtD
Naratriptan—Myalgia—Rosuvastatin—atherosclerosis	0.00211	0.003	CcSEcCtD
Naratriptan—Alopecia—Ezetimibe—atherosclerosis	0.00209	0.00298	CcSEcCtD
Naratriptan—Haemoglobin—Niacin—atherosclerosis	0.00209	0.00296	CcSEcCtD
Naratriptan—Haemorrhage—Niacin—atherosclerosis	0.00208	0.00295	CcSEcCtD
Naratriptan—Hypoaesthesia—Niacin—atherosclerosis	0.00207	0.00293	CcSEcCtD
Naratriptan—Erythema—Ezetimibe—atherosclerosis	0.00206	0.00293	CcSEcCtD
Naratriptan—Confusional state—Rosuvastatin—atherosclerosis	0.00204	0.0029	CcSEcCtD
Naratriptan—Hypoaesthesia—Pravastatin—atherosclerosis	0.00203	0.00289	CcSEcCtD
Naratriptan—Chills—Simvastatin—atherosclerosis	0.00203	0.00288	CcSEcCtD
Naratriptan—Muscle spasms—Lovastatin—atherosclerosis	0.00202	0.00287	CcSEcCtD
Naratriptan—Infection—Rosuvastatin—atherosclerosis	0.00201	0.00286	CcSEcCtD
Naratriptan—Alopecia—Simvastatin—atherosclerosis	0.002	0.00284	CcSEcCtD
Naratriptan—Nervous system disorder—Rosuvastatin—atherosclerosis	0.00199	0.00282	CcSEcCtD
Naratriptan—Muscle spasms—Ezetimibe—atherosclerosis	0.00198	0.00282	CcSEcCtD
Naratriptan—Thrombocytopenia—Rosuvastatin—atherosclerosis	0.00198	0.00282	CcSEcCtD
Naratriptan—Vision blurred—Lovastatin—atherosclerosis	0.00198	0.00282	CcSEcCtD
Naratriptan—Tremor—Lovastatin—atherosclerosis	0.00197	0.0028	CcSEcCtD
Naratriptan—Erythema—Simvastatin—atherosclerosis	0.00197	0.0028	CcSEcCtD
Naratriptan—Ill-defined disorder—Lovastatin—atherosclerosis	0.00195	0.00277	CcSEcCtD
Naratriptan—Tinnitus—Niacin—atherosclerosis	0.00194	0.00275	CcSEcCtD
Naratriptan—Ill-defined disorder—Ezetimibe—atherosclerosis	0.00191	0.00272	CcSEcCtD
Naratriptan—Anaemia—Ezetimibe—atherosclerosis	0.00191	0.00271	CcSEcCtD
Naratriptan—Tinnitus—Pravastatin—atherosclerosis	0.00191	0.00271	CcSEcCtD
Naratriptan—Malaise—Lovastatin—atherosclerosis	0.0019	0.00269	CcSEcCtD
Naratriptan—Cardiac disorder—Pravastatin—atherosclerosis	0.0019	0.00269	CcSEcCtD
Naratriptan—Muscle spasms—Simvastatin—atherosclerosis	0.00189	0.00269	CcSEcCtD
Naratriptan—Vertigo—Lovastatin—atherosclerosis	0.00189	0.00268	CcSEcCtD
Naratriptan—Angiopathy—Niacin—atherosclerosis	0.00188	0.00268	CcSEcCtD
Naratriptan—Chills—Niacin—atherosclerosis	0.00186	0.00265	CcSEcCtD
Naratriptan—Malaise—Ezetimibe—atherosclerosis	0.00186	0.00264	CcSEcCtD
Naratriptan—Vision blurred—Simvastatin—atherosclerosis	0.00185	0.00263	CcSEcCtD
Naratriptan—Arrhythmia—Niacin—atherosclerosis	0.00185	0.00263	CcSEcCtD
Naratriptan—Musculoskeletal discomfort—Rosuvastatin—atherosclerosis	0.00185	0.00262	CcSEcCtD
Naratriptan—Tremor—Simvastatin—atherosclerosis	0.00184	0.00262	CcSEcCtD
Naratriptan—Alopecia—Niacin—atherosclerosis	0.00183	0.00261	CcSEcCtD
Naratriptan—Chills—Pravastatin—atherosclerosis	0.00183	0.0026	CcSEcCtD
Naratriptan—Ill-defined disorder—Simvastatin—atherosclerosis	0.00183	0.00259	CcSEcCtD
Naratriptan—Arrhythmia—Pravastatin—atherosclerosis	0.00183	0.00259	CcSEcCtD
Naratriptan—Palpitations—Ezetimibe—atherosclerosis	0.00182	0.00259	CcSEcCtD
Naratriptan—Paraesthesia—Rosuvastatin—atherosclerosis	0.00182	0.00258	CcSEcCtD
Naratriptan—Anaemia—Simvastatin—atherosclerosis	0.00182	0.00258	CcSEcCtD
Naratriptan—Erythema—Niacin—atherosclerosis	0.00181	0.00257	CcSEcCtD
Naratriptan—Alopecia—Pravastatin—atherosclerosis	0.00181	0.00257	CcSEcCtD
Naratriptan—Cough—Ezetimibe—atherosclerosis	0.0018	0.00256	CcSEcCtD
Naratriptan—Myalgia—Lovastatin—atherosclerosis	0.00179	0.00254	CcSEcCtD
Naratriptan—Arthralgia—Lovastatin—atherosclerosis	0.00179	0.00254	CcSEcCtD
Naratriptan—Anxiety—Lovastatin—atherosclerosis	0.00178	0.00254	CcSEcCtD
Naratriptan—Malaise—Simvastatin—atherosclerosis	0.00177	0.00252	CcSEcCtD
Naratriptan—Discomfort—Lovastatin—atherosclerosis	0.00177	0.00251	CcSEcCtD
Naratriptan—Vertigo—Simvastatin—atherosclerosis	0.00177	0.00251	CcSEcCtD
Naratriptan—Myalgia—Ezetimibe—atherosclerosis	0.00176	0.0025	CcSEcCtD
Naratriptan—Arthralgia—Ezetimibe—atherosclerosis	0.00176	0.0025	CcSEcCtD
Naratriptan—Dry mouth—Lovastatin—atherosclerosis	0.00175	0.00249	CcSEcCtD
Naratriptan—Muscle spasms—Niacin—atherosclerosis	0.00174	0.00247	CcSEcCtD
Naratriptan—Discomfort—Ezetimibe—atherosclerosis	0.00174	0.00247	CcSEcCtD
Naratriptan—Constipation—Rosuvastatin—atherosclerosis	0.00173	0.00246	CcSEcCtD
Naratriptan—Pain—Rosuvastatin—atherosclerosis	0.00173	0.00246	CcSEcCtD
Naratriptan—Confusional state—Lovastatin—atherosclerosis	0.00173	0.00246	CcSEcCtD
Naratriptan—Dry mouth—Ezetimibe—atherosclerosis	0.00172	0.00244	CcSEcCtD
Naratriptan—Anaphylactic shock—Lovastatin—atherosclerosis	0.00172	0.00244	CcSEcCtD
Naratriptan—Muscle spasms—Pravastatin—atherosclerosis	0.00171	0.00243	CcSEcCtD
Naratriptan—Infection—Lovastatin—atherosclerosis	0.00171	0.00242	CcSEcCtD
Naratriptan—Vision blurred—Niacin—atherosclerosis	0.0017	0.00242	CcSEcCtD
Naratriptan—Confusional state—Ezetimibe—atherosclerosis	0.0017	0.00241	CcSEcCtD
Naratriptan—Anaphylactic shock—Ezetimibe—atherosclerosis	0.00168	0.00239	CcSEcCtD
Naratriptan—Thrombocytopenia—Lovastatin—atherosclerosis	0.00168	0.00239	CcSEcCtD
Naratriptan—Vision blurred—Pravastatin—atherosclerosis	0.00168	0.00238	CcSEcCtD
Naratriptan—Arthralgia—Simvastatin—atherosclerosis	0.00168	0.00238	CcSEcCtD
Naratriptan—Myalgia—Simvastatin—atherosclerosis	0.00168	0.00238	CcSEcCtD
Naratriptan—Infection—Ezetimibe—atherosclerosis	0.00167	0.00238	CcSEcCtD
Naratriptan—Feeling abnormal—Rosuvastatin—atherosclerosis	0.00167	0.00237	CcSEcCtD
Naratriptan—Anxiety—Simvastatin—atherosclerosis	0.00167	0.00237	CcSEcCtD
Naratriptan—Tremor—Pravastatin—atherosclerosis	0.00167	0.00237	CcSEcCtD
Naratriptan—Discomfort—Simvastatin—atherosclerosis	0.00166	0.00235	CcSEcCtD
Naratriptan—Nervous system disorder—Ezetimibe—atherosclerosis	0.00165	0.00235	CcSEcCtD
Naratriptan—Ill-defined disorder—Pravastatin—atherosclerosis	0.00165	0.00234	CcSEcCtD
Naratriptan—Thrombocytopenia—Ezetimibe—atherosclerosis	0.00165	0.00234	CcSEcCtD
Naratriptan—Anaemia—Pravastatin—atherosclerosis	0.00164	0.00234	CcSEcCtD
Naratriptan—Skin disorder—Ezetimibe—atherosclerosis	0.00164	0.00232	CcSEcCtD
Naratriptan—Vertigo—Niacin—atherosclerosis	0.00162	0.00231	CcSEcCtD
Naratriptan—Syncope—Niacin—atherosclerosis	0.00162	0.0023	CcSEcCtD
Naratriptan—Confusional state—Simvastatin—atherosclerosis	0.00162	0.0023	CcSEcCtD
Naratriptan—Urticaria—Rosuvastatin—atherosclerosis	0.00161	0.00229	CcSEcCtD
Naratriptan—Oedema—Simvastatin—atherosclerosis	0.00161	0.00228	CcSEcCtD
Naratriptan—Anaphylactic shock—Simvastatin—atherosclerosis	0.00161	0.00228	CcSEcCtD
Naratriptan—Malaise—Pravastatin—atherosclerosis	0.0016	0.00228	CcSEcCtD
Naratriptan—Vertigo—Pravastatin—atherosclerosis	0.0016	0.00227	CcSEcCtD
Naratriptan—Palpitations—Niacin—atherosclerosis	0.0016	0.00227	CcSEcCtD
Naratriptan—Infection—Simvastatin—atherosclerosis	0.0016	0.00227	CcSEcCtD
Naratriptan—Loss of consciousness—Niacin—atherosclerosis	0.00159	0.00226	CcSEcCtD
Naratriptan—Cough—Niacin—atherosclerosis	0.00158	0.00224	CcSEcCtD
Naratriptan—Thrombocytopenia—Simvastatin—atherosclerosis	0.00157	0.00223	CcSEcCtD
Naratriptan—Musculoskeletal discomfort—Lovastatin—atherosclerosis	0.00156	0.00222	CcSEcCtD
Naratriptan—Cough—Pravastatin—atherosclerosis	0.00155	0.00221	CcSEcCtD
Naratriptan—Paraesthesia—Lovastatin—atherosclerosis	0.00154	0.00219	CcSEcCtD
Naratriptan—Myalgia—Niacin—atherosclerosis	0.00154	0.00219	CcSEcCtD
Naratriptan—Arthralgia—Niacin—atherosclerosis	0.00154	0.00219	CcSEcCtD
Naratriptan—Musculoskeletal discomfort—Ezetimibe—atherosclerosis	0.00153	0.00218	CcSEcCtD
Naratriptan—Dyspnoea—Lovastatin—atherosclerosis	0.00153	0.00217	CcSEcCtD
Naratriptan—Myalgia—Pravastatin—atherosclerosis	0.00151	0.00215	CcSEcCtD
Naratriptan—Arthralgia—Pravastatin—atherosclerosis	0.00151	0.00215	CcSEcCtD
Naratriptan—Paraesthesia—Ezetimibe—atherosclerosis	0.00151	0.00215	CcSEcCtD
Naratriptan—Anxiety—Pravastatin—atherosclerosis	0.00151	0.00214	CcSEcCtD
Naratriptan—Dry mouth—Niacin—atherosclerosis	0.0015	0.00214	CcSEcCtD
Naratriptan—Dyspnoea—Ezetimibe—atherosclerosis	0.0015	0.00213	CcSEcCtD
Naratriptan—Discomfort—Pravastatin—atherosclerosis	0.0015	0.00213	CcSEcCtD
Naratriptan—Hypersensitivity—Rosuvastatin—atherosclerosis	0.00149	0.00212	CcSEcCtD
Naratriptan—Fatigue—Lovastatin—atherosclerosis	0.00148	0.0021	CcSEcCtD
Naratriptan—Anaphylactic shock—Niacin—atherosclerosis	0.00147	0.00209	CcSEcCtD
Naratriptan—Oedema—Niacin—atherosclerosis	0.00147	0.00209	CcSEcCtD
Naratriptan—Constipation—Lovastatin—atherosclerosis	0.00147	0.00209	CcSEcCtD
Naratriptan—Pain—Lovastatin—atherosclerosis	0.00147	0.00209	CcSEcCtD
Naratriptan—Confusional state—Pravastatin—atherosclerosis	0.00146	0.00208	CcSEcCtD
Naratriptan—Musculoskeletal discomfort—Simvastatin—atherosclerosis	0.00146	0.00208	CcSEcCtD
Naratriptan—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.00145	0.00207	CcSEcCtD
Naratriptan—Asthenia—Rosuvastatin—atherosclerosis	0.00145	0.00206	CcSEcCtD
Naratriptan—Anaphylactic shock—Pravastatin—atherosclerosis	0.00145	0.00206	CcSEcCtD
Naratriptan—Oedema—Pravastatin—atherosclerosis	0.00145	0.00206	CcSEcCtD
Naratriptan—Fatigue—Ezetimibe—atherosclerosis	0.00145	0.00206	CcSEcCtD
Naratriptan—Shock—Niacin—atherosclerosis	0.00145	0.00206	CcSEcCtD
Naratriptan—Infection—Pravastatin—atherosclerosis	0.00144	0.00205	CcSEcCtD
Naratriptan—Paraesthesia—Simvastatin—atherosclerosis	0.00144	0.00205	CcSEcCtD
Naratriptan—Pain—Ezetimibe—atherosclerosis	0.00144	0.00205	CcSEcCtD
Naratriptan—Constipation—Ezetimibe—atherosclerosis	0.00144	0.00205	CcSEcCtD
Naratriptan—Pruritus—Rosuvastatin—atherosclerosis	0.00143	0.00204	CcSEcCtD
Naratriptan—Skin disorder—Niacin—atherosclerosis	0.00143	0.00203	CcSEcCtD
Naratriptan—Dyspnoea—Simvastatin—atherosclerosis	0.00143	0.00203	CcSEcCtD
Naratriptan—Hyperhidrosis—Niacin—atherosclerosis	0.00143	0.00203	CcSEcCtD
Naratriptan—Thrombocytopenia—Pravastatin—atherosclerosis	0.00142	0.00202	CcSEcCtD
Naratriptan—Feeling abnormal—Lovastatin—atherosclerosis	0.00141	0.00201	CcSEcCtD
Naratriptan—Hyperhidrosis—Pravastatin—atherosclerosis	0.0014	0.00199	CcSEcCtD
Naratriptan—Feeling abnormal—Ezetimibe—atherosclerosis	0.00139	0.00197	CcSEcCtD
Naratriptan—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.00139	0.00197	CcSEcCtD
Naratriptan—Diarrhoea—Rosuvastatin—atherosclerosis	0.00139	0.00197	CcSEcCtD
Naratriptan—Fatigue—Simvastatin—atherosclerosis	0.00138	0.00197	CcSEcCtD
Naratriptan—Hypotension—Niacin—atherosclerosis	0.00138	0.00196	CcSEcCtD
Naratriptan—Constipation—Simvastatin—atherosclerosis	0.00137	0.00195	CcSEcCtD
Naratriptan—Pain—Simvastatin—atherosclerosis	0.00137	0.00195	CcSEcCtD
Naratriptan—Urticaria—Lovastatin—atherosclerosis	0.00136	0.00194	CcSEcCtD
Naratriptan—Body temperature increased—Lovastatin—atherosclerosis	0.00136	0.00193	CcSEcCtD
Naratriptan—Musculoskeletal discomfort—Niacin—atherosclerosis	0.00134	0.00191	CcSEcCtD
Naratriptan—Dizziness—Rosuvastatin—atherosclerosis	0.00134	0.0019	CcSEcCtD
Naratriptan—Urticaria—Ezetimibe—atherosclerosis	0.00134	0.0019	CcSEcCtD
Naratriptan—Body temperature increased—Ezetimibe—atherosclerosis	0.00133	0.00189	CcSEcCtD
Naratriptan—Paraesthesia—Niacin—atherosclerosis	0.00132	0.00188	CcSEcCtD
Naratriptan—Feeling abnormal—Simvastatin—atherosclerosis	0.00132	0.00188	CcSEcCtD
Naratriptan—Musculoskeletal discomfort—Pravastatin—atherosclerosis	0.00132	0.00188	CcSEcCtD
Naratriptan—Dyspnoea—Niacin—atherosclerosis	0.00131	0.00187	CcSEcCtD
Naratriptan—Somnolence—Niacin—atherosclerosis	0.00131	0.00186	CcSEcCtD
Naratriptan—Paraesthesia—Pravastatin—atherosclerosis	0.0013	0.00185	CcSEcCtD
Naratriptan—Dyspnoea—Pravastatin—atherosclerosis	0.00129	0.00184	CcSEcCtD
Naratriptan—Rash—Rosuvastatin—atherosclerosis	0.00128	0.00181	CcSEcCtD
Naratriptan—Dermatitis—Rosuvastatin—atherosclerosis	0.00128	0.00181	CcSEcCtD
Naratriptan—Urticaria—Simvastatin—atherosclerosis	0.00128	0.00181	CcSEcCtD
Naratriptan—Gastrointestinal disorder—Niacin—atherosclerosis	0.00127	0.00181	CcSEcCtD
Naratriptan—Body temperature increased—Simvastatin—atherosclerosis	0.00127	0.0018	CcSEcCtD
Naratriptan—Headache—Rosuvastatin—atherosclerosis	0.00127	0.0018	CcSEcCtD
Naratriptan—Hypersensitivity—Lovastatin—atherosclerosis	0.00127	0.0018	CcSEcCtD
Naratriptan—Pain—Niacin—atherosclerosis	0.00126	0.00179	CcSEcCtD
Naratriptan—Fatigue—Pravastatin—atherosclerosis	0.00125	0.00178	CcSEcCtD
Naratriptan—Pain—Pravastatin—atherosclerosis	0.00124	0.00176	CcSEcCtD
Naratriptan—Constipation—Pravastatin—atherosclerosis	0.00124	0.00176	CcSEcCtD
Naratriptan—Hypersensitivity—Ezetimibe—atherosclerosis	0.00124	0.00176	CcSEcCtD
Naratriptan—Asthenia—Lovastatin—atherosclerosis	0.00123	0.00175	CcSEcCtD
Naratriptan—Pruritus—Lovastatin—atherosclerosis	0.00121	0.00173	CcSEcCtD
Naratriptan—Asthenia—Ezetimibe—atherosclerosis	0.00121	0.00172	CcSEcCtD
Naratriptan—Nausea—Rosuvastatin—atherosclerosis	0.0012	0.00171	CcSEcCtD
Naratriptan—Feeling abnormal—Pravastatin—atherosclerosis	0.0012	0.0017	CcSEcCtD
Naratriptan—Pruritus—Ezetimibe—atherosclerosis	0.00119	0.00169	CcSEcCtD
Naratriptan—Hypersensitivity—Simvastatin—atherosclerosis	0.00118	0.00168	CcSEcCtD
Naratriptan—Diarrhoea—Lovastatin—atherosclerosis	0.00117	0.00167	CcSEcCtD
Naratriptan—Urticaria—Niacin—atherosclerosis	0.00117	0.00166	CcSEcCtD
Naratriptan—Body temperature increased—Niacin—atherosclerosis	0.00117	0.00166	CcSEcCtD
Naratriptan—Urticaria—Pravastatin—atherosclerosis	0.00115	0.00164	CcSEcCtD
Naratriptan—Asthenia—Simvastatin—atherosclerosis	0.00115	0.00164	CcSEcCtD
Naratriptan—Diarrhoea—Ezetimibe—atherosclerosis	0.00115	0.00164	CcSEcCtD
Naratriptan—Body temperature increased—Pravastatin—atherosclerosis	0.00115	0.00163	CcSEcCtD
Naratriptan—Pruritus—Simvastatin—atherosclerosis	0.00114	0.00161	CcSEcCtD
Naratriptan—Dizziness—Lovastatin—atherosclerosis	0.00114	0.00161	CcSEcCtD
Naratriptan—HTR1D—connective tissue—atherosclerosis	0.00113	0.0668	CbGeAlD
Naratriptan—Dizziness—Ezetimibe—atherosclerosis	0.00111	0.00158	CcSEcCtD
Naratriptan—Diarrhoea—Simvastatin—atherosclerosis	0.0011	0.00156	CcSEcCtD
Naratriptan—Vomiting—Lovastatin—atherosclerosis	0.00109	0.00155	CcSEcCtD
Naratriptan—Hypersensitivity—Niacin—atherosclerosis	0.00109	0.00154	CcSEcCtD
Naratriptan—Rash—Lovastatin—atherosclerosis	0.00108	0.00154	CcSEcCtD
Naratriptan—Dermatitis—Lovastatin—atherosclerosis	0.00108	0.00154	CcSEcCtD
Naratriptan—Headache—Lovastatin—atherosclerosis	0.00108	0.00153	CcSEcCtD
Naratriptan—Vomiting—Ezetimibe—atherosclerosis	0.00107	0.00152	CcSEcCtD
Naratriptan—Hypersensitivity—Pravastatin—atherosclerosis	0.00107	0.00152	CcSEcCtD
Naratriptan—Dizziness—Simvastatin—atherosclerosis	0.00106	0.00151	CcSEcCtD
Naratriptan—Rash—Ezetimibe—atherosclerosis	0.00106	0.00151	CcSEcCtD
Naratriptan—Dermatitis—Ezetimibe—atherosclerosis	0.00106	0.00151	CcSEcCtD
Naratriptan—Asthenia—Niacin—atherosclerosis	0.00106	0.0015	CcSEcCtD
Naratriptan—Headache—Ezetimibe—atherosclerosis	0.00106	0.0015	CcSEcCtD
Naratriptan—Pruritus—Niacin—atherosclerosis	0.00104	0.00148	CcSEcCtD
Naratriptan—Asthenia—Pravastatin—atherosclerosis	0.00104	0.00148	CcSEcCtD
Naratriptan—Pruritus—Pravastatin—atherosclerosis	0.00103	0.00146	CcSEcCtD
Naratriptan—Vomiting—Simvastatin—atherosclerosis	0.00102	0.00145	CcSEcCtD
Naratriptan—Nausea—Lovastatin—atherosclerosis	0.00102	0.00145	CcSEcCtD
Naratriptan—Rash—Simvastatin—atherosclerosis	0.00101	0.00144	CcSEcCtD
Naratriptan—Dermatitis—Simvastatin—atherosclerosis	0.00101	0.00144	CcSEcCtD
Naratriptan—HTR1B—cardiovascular system—atherosclerosis	0.00101	0.0601	CbGeAlD
Naratriptan—Diarrhoea—Niacin—atherosclerosis	0.00101	0.00143	CcSEcCtD
Naratriptan—Headache—Simvastatin—atherosclerosis	0.00101	0.00143	CcSEcCtD
Naratriptan—Nausea—Ezetimibe—atherosclerosis	0.001	0.00142	CcSEcCtD
Naratriptan—Diarrhoea—Pravastatin—atherosclerosis	0.000993	0.00141	CcSEcCtD
Naratriptan—HTR1D—cardiovascular system—atherosclerosis	0.000979	0.0581	CbGeAlD
Naratriptan—Dizziness—Niacin—atherosclerosis	0.000975	0.00139	CcSEcCtD
Naratriptan—Dizziness—Pravastatin—atherosclerosis	0.00096	0.00136	CcSEcCtD
Naratriptan—Nausea—Simvastatin—atherosclerosis	0.000954	0.00136	CcSEcCtD
Naratriptan—Vomiting—Niacin—atherosclerosis	0.000938	0.00133	CcSEcCtD
Naratriptan—Rash—Niacin—atherosclerosis	0.00093	0.00132	CcSEcCtD
Naratriptan—Dermatitis—Niacin—atherosclerosis	0.000929	0.00132	CcSEcCtD
Naratriptan—Headache—Niacin—atherosclerosis	0.000924	0.00131	CcSEcCtD
Naratriptan—Vomiting—Pravastatin—atherosclerosis	0.000923	0.00131	CcSEcCtD
Naratriptan—Rash—Pravastatin—atherosclerosis	0.000915	0.0013	CcSEcCtD
Naratriptan—Dermatitis—Pravastatin—atherosclerosis	0.000915	0.0013	CcSEcCtD
Naratriptan—Headache—Pravastatin—atherosclerosis	0.00091	0.00129	CcSEcCtD
Naratriptan—Nausea—Niacin—atherosclerosis	0.000876	0.00124	CcSEcCtD
Naratriptan—Nausea—Pravastatin—atherosclerosis	0.000862	0.00123	CcSEcCtD
Naratriptan—MAOA—connective tissue—atherosclerosis	0.000857	0.0509	CbGeAlD
Naratriptan—HTR1A—cardiovascular system—atherosclerosis	0.000816	0.0485	CbGeAlD
Naratriptan—MAOA—cardiovascular system—atherosclerosis	0.000746	0.0443	CbGeAlD
Naratriptan—MAOA—adipose tissue—atherosclerosis	0.000658	0.039	CbGeAlD
Naratriptan—MAOA—liver—atherosclerosis	0.000461	0.0274	CbGeAlD
Naratriptan—HTR1A—Signaling Pathways—APOA2—atherosclerosis	0.000133	0.000478	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—EDN1—atherosclerosis	0.000133	0.000477	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—PRKCG—atherosclerosis	0.000133	0.000477	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—VWF—atherosclerosis	0.000133	0.000475	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—CCL5—atherosclerosis	0.000132	0.000474	CbGpPWpGaD
Naratriptan—HTR1D—GPCR downstream signaling—AGT—atherosclerosis	0.000132	0.000472	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—APOC3—atherosclerosis	0.000132	0.000472	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—SCARB1—atherosclerosis	0.000131	0.00047	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—LDLR—atherosclerosis	0.000131	0.000469	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—CCL3—atherosclerosis	0.000131	0.000468	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—LPL—atherosclerosis	0.000129	0.000463	CbGpPWpGaD
Naratriptan—HTR1B—GPCR downstream signaling—AGT—atherosclerosis	0.000129	0.000462	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—CCL3—atherosclerosis	0.000128	0.000458	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—KNG1—atherosclerosis	0.000128	0.000457	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—UTS2—atherosclerosis	0.000127	0.000456	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—AGTR1—atherosclerosis	0.000127	0.000455	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—PRKCG—atherosclerosis	0.000126	0.00045	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—NCF1—atherosclerosis	0.000125	0.000448	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—HMGCR—atherosclerosis	0.000124	0.000444	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—NCF1—atherosclerosis	0.000123	0.000439	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—SPP1—atherosclerosis	0.000122	0.000439	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—CX3CR1—atherosclerosis	0.000122	0.000437	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—CASR—atherosclerosis	0.000122	0.000437	CbGpPWpGaD
Naratriptan—HTR1F—Signaling by GPCR—CXCL8—atherosclerosis	0.000122	0.000437	CbGpPWpGaD
Naratriptan—HTR1D—GPCR downstream signaling—F2—atherosclerosis	0.000122	0.000436	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—AGT—atherosclerosis	0.00012	0.000429	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—CX3CL1—atherosclerosis	0.00012	0.000428	CbGpPWpGaD
Naratriptan—HTR1B—GPCR downstream signaling—F2—atherosclerosis	0.000119	0.000427	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—EDN1—atherosclerosis	0.000118	0.000424	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—CCR2—atherosclerosis	0.000118	0.000423	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—EDNRA—atherosclerosis	0.000118	0.000423	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—CYBA—atherosclerosis	0.000118	0.000422	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—CCL5—atherosclerosis	0.000118	0.000421	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—AGT—atherosclerosis	0.000117	0.00042	CbGpPWpGaD
Naratriptan—HTR1D—GPCR downstream signaling—PIK3CG—atherosclerosis	0.000117	0.000418	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—CCR2—atherosclerosis	0.000116	0.000415	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—EDNRA—atherosclerosis	0.000116	0.000415	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—CYBA—atherosclerosis	0.000115	0.000413	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—GHRL—atherosclerosis	0.000115	0.000413	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—PARP1—atherosclerosis	0.000115	0.000413	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—PLAT—atherosclerosis	0.000115	0.000413	CbGpPWpGaD
Naratriptan—HTR1B—GPCR downstream signaling—PIK3CG—atherosclerosis	0.000114	0.000409	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—CNR2—atherosclerosis	0.000113	0.000406	CbGpPWpGaD
Naratriptan—HTR1A—GPCR ligand binding—CXCL8—atherosclerosis	0.000113	0.000406	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—PDGFB—atherosclerosis	0.000113	0.000406	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—MMP3—atherosclerosis	0.000113	0.000405	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—PARP1—atherosclerosis	0.000113	0.000404	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—PLAT—atherosclerosis	0.000113	0.000404	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—GHRL—atherosclerosis	0.000113	0.000404	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—PRKCG—atherosclerosis	0.000112	0.0004	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—F2—atherosclerosis	0.000111	0.000396	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—AGT—atherosclerosis	0.000111	0.000396	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—ABCA1—atherosclerosis	0.000111	0.000396	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—APOE—atherosclerosis	0.000108	0.000388	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—LEP—atherosclerosis	0.000108	0.000388	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—F2—atherosclerosis	0.000108	0.000388	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—EDN1—atherosclerosis	0.000108	0.000385	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—CAV1—atherosclerosis	0.000107	0.000385	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—APOA1—atherosclerosis	0.000107	0.000384	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—CCL5—atherosclerosis	0.000107	0.000382	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—PIK3CG—atherosclerosis	0.000106	0.000379	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—PIK3CG—atherosclerosis	0.000104	0.000371	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—ESR1—atherosclerosis	0.000103	0.000371	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—F2—atherosclerosis	0.000102	0.000366	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—PRKCG—atherosclerosis	0.000101	0.000364	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—KNG1—atherosclerosis	0.000101	0.000362	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—VWF—atherosclerosis	0.000101	0.000362	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—AGTR1—atherosclerosis	0.000101	0.00036	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—APOC3—atherosclerosis	0.0001	0.00036	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—LDLR—atherosclerosis	9.98e-05	0.000358	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—KNG1—atherosclerosis	9.9e-05	0.000355	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—CCL2—atherosclerosis	9.86e-05	0.000353	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—AGTR1—atherosclerosis	9.84e-05	0.000352	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—AGT—atherosclerosis	9.83e-05	0.000352	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—PLG—atherosclerosis	9.79e-05	0.000351	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—PIK3CG—atherosclerosis	9.78e-05	0.00035	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—CCL3—atherosclerosis	9.75e-05	0.000349	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—CCL2—atherosclerosis	9.65e-05	0.000346	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—PLG—atherosclerosis	9.59e-05	0.000344	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—HMOX1—atherosclerosis	9.48e-05	0.00034	CbGpPWpGaD
Naratriptan—HTR1F—Signaling by GPCR—MAPK3—atherosclerosis	9.37e-05	0.000335	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—NCF1—atherosclerosis	9.34e-05	0.000334	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—SOCS3—atherosclerosis	9.27e-05	0.000332	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—INS—atherosclerosis	9.26e-05	0.000332	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—CCL2—atherosclerosis	9.11e-05	0.000326	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—F2—atherosclerosis	9.09e-05	0.000325	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—APOB—atherosclerosis	9.09e-05	0.000325	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—SOCS3—atherosclerosis	9.08e-05	0.000325	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—MMP3—atherosclerosis	8.96e-05	0.000321	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—IGF1—atherosclerosis	8.95e-05	0.000321	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—AGT—atherosclerosis	8.93e-05	0.00032	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—IGF2—atherosclerosis	8.92e-05	0.000319	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—GSTM1—atherosclerosis	8.84e-05	0.000317	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—CCR2—atherosclerosis	8.82e-05	0.000316	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—EDNRA—atherosclerosis	8.82e-05	0.000316	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—CYBA—atherosclerosis	8.78e-05	0.000314	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—MMP3—atherosclerosis	8.77e-05	0.000314	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—IGF2—atherosclerosis	8.73e-05	0.000313	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—PIK3CG—atherosclerosis	8.7e-05	0.000311	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—LPL—atherosclerosis	8.68e-05	0.000311	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—APOB—atherosclerosis	8.66e-05	0.00031	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—PARP1—atherosclerosis	8.59e-05	0.000308	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—GHRL—atherosclerosis	8.59e-05	0.000308	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—PLAT—atherosclerosis	8.59e-05	0.000308	CbGpPWpGaD
Naratriptan—HTR1D—GPCR downstream signaling—CXCL8—atherosclerosis	8.58e-05	0.000307	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—EDN1—atherosclerosis	8.52e-05	0.000305	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—SERPINE1—atherosclerosis	8.5e-05	0.000305	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—APOB—atherosclerosis	8.48e-05	0.000304	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—GPX1—atherosclerosis	8.46e-05	0.000303	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—CCL5—atherosclerosis	8.45e-05	0.000303	CbGpPWpGaD
Naratriptan—HTR1B—GPCR downstream signaling—CXCL8—atherosclerosis	8.41e-05	0.000301	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—EDN1—atherosclerosis	8.34e-05	0.000299	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—CCL5—atherosclerosis	8.28e-05	0.000297	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—LPL—atherosclerosis	8.27e-05	0.000296	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—F2—atherosclerosis	8.25e-05	0.000296	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—CD36—atherosclerosis	8.24e-05	0.000295	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—NOS3—atherosclerosis	8.12e-05	0.000291	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—LPL—atherosclerosis	8.09e-05	0.00029	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—PRKCG—atherosclerosis	8.04e-05	0.000288	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—PIK3CG—atherosclerosis	7.9e-05	0.000283	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—PRKCG—atherosclerosis	7.87e-05	0.000282	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—SPP1—atherosclerosis	7.83e-05	0.00028	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—MTHFR—atherosclerosis	7.81e-05	0.00028	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—CXCL8—atherosclerosis	7.8e-05	0.000279	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—SPP1—atherosclerosis	7.67e-05	0.000275	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—PPARA—atherosclerosis	7.66e-05	0.000274	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—CXCL8—atherosclerosis	7.63e-05	0.000273	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—KNG1—atherosclerosis	7.54e-05	0.00027	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—AGTR1—atherosclerosis	7.5e-05	0.000269	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—AGT—atherosclerosis	7.42e-05	0.000266	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—CCL2—atherosclerosis	7.35e-05	0.000263	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—PLG—atherosclerosis	7.31e-05	0.000262	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—APOE—atherosclerosis	7.27e-05	0.00026	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—PDGFB—atherosclerosis	7.24e-05	0.000259	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—CAV1—atherosclerosis	7.2e-05	0.000258	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—CXCL8—atherosclerosis	7.2e-05	0.000258	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—APOA1—atherosclerosis	7.19e-05	0.000257	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—PDGFB—atherosclerosis	7.09e-05	0.000254	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—AGT—atherosclerosis	7.07e-05	0.000253	CbGpPWpGaD
Naratriptan—HTR1F—GPCR downstream signaling—AKT1—atherosclerosis	6.96e-05	0.000249	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—LEP—atherosclerosis	6.93e-05	0.000248	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—APOE—atherosclerosis	6.93e-05	0.000248	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—AGT—atherosclerosis	6.92e-05	0.000248	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—SOCS3—atherosclerosis	6.92e-05	0.000248	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—CAV1—atherosclerosis	6.87e-05	0.000246	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—APOA1—atherosclerosis	6.85e-05	0.000245	CbGpPWpGaD
Naratriptan—HTR1F—Signaling by GPCR—IL6—atherosclerosis	6.85e-05	0.000245	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—LEP—atherosclerosis	6.78e-05	0.000243	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—APOE—atherosclerosis	6.78e-05	0.000243	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—CAV1—atherosclerosis	6.72e-05	0.000241	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—APOA1—atherosclerosis	6.71e-05	0.00024	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—MMP3—atherosclerosis	6.68e-05	0.000239	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—IGF2—atherosclerosis	6.65e-05	0.000238	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—ESR1—atherosclerosis	6.62e-05	0.000237	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—PIK3CG—atherosclerosis	6.56e-05	0.000235	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—F2—atherosclerosis	6.53e-05	0.000234	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—MMP9—atherosclerosis	6.51e-05	0.000233	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—ESR1—atherosclerosis	6.48e-05	0.000232	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—APOB—atherosclerosis	6.46e-05	0.000231	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—NFKB1—atherosclerosis	6.44e-05	0.000231	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—CXCL8—atherosclerosis	6.4e-05	0.000229	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—F2—atherosclerosis	6.4e-05	0.000229	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—EDN1—atherosclerosis	6.36e-05	0.000228	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—MAPK8—atherosclerosis	6.33e-05	0.000227	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—PPARG—atherosclerosis	6.33e-05	0.000227	CbGpPWpGaD
Naratriptan—HTR1F—Signaling by GPCR—AKT1—atherosclerosis	6.32e-05	0.000226	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—CCL5—atherosclerosis	6.31e-05	0.000226	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—PIK3CG—atherosclerosis	6.25e-05	0.000224	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—INS—atherosclerosis	6.21e-05	0.000223	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—LPL—atherosclerosis	6.17e-05	0.000221	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—PIK3CG—atherosclerosis	6.12e-05	0.000219	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—PRKCG—atherosclerosis	6e-05	0.000215	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—MAPK3—atherosclerosis	5.99e-05	0.000215	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—INS—atherosclerosis	5.92e-05	0.000212	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—MAPK3—atherosclerosis	5.86e-05	0.00021	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—VEGFA—atherosclerosis	5.85e-05	0.000209	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—SPP1—atherosclerosis	5.84e-05	0.000209	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—CCL2—atherosclerosis	5.82e-05	0.000209	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—CXCL8—atherosclerosis	5.81e-05	0.000208	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—INS—atherosclerosis	5.8e-05	0.000208	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—STAT3—atherosclerosis	5.79e-05	0.000207	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—IGF1—atherosclerosis	5.73e-05	0.000205	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—CCL2—atherosclerosis	5.7e-05	0.000204	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—ALB—atherosclerosis	5.7e-05	0.000204	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—IGF1—atherosclerosis	5.61e-05	0.000201	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—MAPK3—atherosclerosis	5.53e-05	0.000198	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—NOS3—atherosclerosis	5.45e-05	0.000195	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—SERPINE1—atherosclerosis	5.44e-05	0.000195	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—PDGFB—atherosclerosis	5.4e-05	0.000194	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—TGFB1—atherosclerosis	5.37e-05	0.000192	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—SERPINE1—atherosclerosis	5.32e-05	0.000191	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—AGT—atherosclerosis	5.28e-05	0.000189	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—NOS3—atherosclerosis	5.19e-05	0.000186	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—APOE—atherosclerosis	5.17e-05	0.000185	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—LEP—atherosclerosis	5.17e-05	0.000185	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—CAV1—atherosclerosis	5.12e-05	0.000183	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—APOA1—atherosclerosis	5.11e-05	0.000183	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—NOS3—atherosclerosis	5.08e-05	0.000182	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—PTGS2—atherosclerosis	4.98e-05	0.000178	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—ESR1—atherosclerosis	4.93e-05	0.000177	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—F2—atherosclerosis	4.87e-05	0.000175	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—PIK3CG—atherosclerosis	4.66e-05	0.000167	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—CXCL8—atherosclerosis	4.6e-05	0.000165	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—CXCL8—atherosclerosis	4.51e-05	0.000162	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—MAPK3—atherosclerosis	4.47e-05	0.00016	CbGpPWpGaD
Naratriptan—HTR1D—GPCR downstream signaling—AKT1—atherosclerosis	4.45e-05	0.000159	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—INS—atherosclerosis	4.42e-05	0.000158	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—IL6—atherosclerosis	4.38e-05	0.000157	CbGpPWpGaD
Naratriptan—HTR1B—GPCR downstream signaling—AKT1—atherosclerosis	4.36e-05	0.000156	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—CCL2—atherosclerosis	4.34e-05	0.000156	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—IL6—atherosclerosis	4.29e-05	0.000154	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—IGF1—atherosclerosis	4.27e-05	0.000153	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—MMP9—atherosclerosis	4.16e-05	0.000149	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—NFKB1—atherosclerosis	4.12e-05	0.000148	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—MMP9—atherosclerosis	4.08e-05	0.000146	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—SERPINE1—atherosclerosis	4.06e-05	0.000145	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—MAPK8—atherosclerosis	4.05e-05	0.000145	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—IL6—atherosclerosis	4.04e-05	0.000145	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—AKT1—atherosclerosis	4.04e-05	0.000145	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—NFKB1—atherosclerosis	4.03e-05	0.000145	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—MAPK8—atherosclerosis	3.97e-05	0.000142	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—AKT1—atherosclerosis	3.96e-05	0.000142	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—NOS3—atherosclerosis	3.87e-05	0.000139	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—VEGFA—atherosclerosis	3.74e-05	0.000134	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—AKT1—atherosclerosis	3.73e-05	0.000134	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—STAT3—atherosclerosis	3.7e-05	0.000133	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—VEGFA—atherosclerosis	3.66e-05	0.000131	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—STAT3—atherosclerosis	3.63e-05	0.00013	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—MAPK3—atherosclerosis	3.54e-05	0.000127	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—MAPK3—atherosclerosis	3.46e-05	0.000124	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—CXCL8—atherosclerosis	3.43e-05	0.000123	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—TGFB1—atherosclerosis	3.43e-05	0.000123	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—TGFB1—atherosclerosis	3.36e-05	0.00012	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—AKT1—atherosclerosis	3.32e-05	0.000119	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—IL6—atherosclerosis	3.27e-05	0.000117	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—MMP9—atherosclerosis	3.11e-05	0.000111	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—NFKB1—atherosclerosis	3.07e-05	0.00011	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—MAPK8—atherosclerosis	3.02e-05	0.000108	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—AKT1—atherosclerosis	3.01e-05	0.000108	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—VEGFA—atherosclerosis	2.79e-05	9.99e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—STAT3—atherosclerosis	2.76e-05	9.89e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—MAPK3—atherosclerosis	2.64e-05	9.45e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—IL6—atherosclerosis	2.59e-05	9.27e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—TGFB1—atherosclerosis	2.56e-05	9.17e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—IL6—atherosclerosis	2.53e-05	9.07e-05	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—AKT1—atherosclerosis	2.5e-05	8.97e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—AKT1—atherosclerosis	2.39e-05	8.55e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—AKT1—atherosclerosis	2.34e-05	8.37e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—IL6—atherosclerosis	1.93e-05	6.91e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—AKT1—atherosclerosis	1.78e-05	6.38e-05	CbGpPWpGaD
